Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03680092
Other study ID # 180383
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 26, 2019
Est. completion date December 2027

Study information

Verified date April 2024
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs when the cells from your donor (the graft) see your body's cells (the host) as different and attack them.


Description:

The experimental GVHD prophylaxis arm consists of cyclophosphamide and abatacept. Cyclophosphamide induces apoptosis of activated T cells and abatacept (CTLA4Ig) blocks activation of T cells by inhibiting the co-stimulatory signal. Compared to the standard-of-care control arm, the experimental arm is much more convenient and expected to be associated with fewer toxicities. In addition there is a great theoretical potential for immunological synergy between cyclophosphamide and abatacept for inducing post-transplant immunologic tolerance that clinically might translate into less GVHD without increase in relapse Patients will be randomized 1:1 to the experimental vs the standard of care arm. Randomization will be done prior to the use of any conditional therapy. The two arms will be stratified by disease (acute leukemia vs others) and donor type (MRD vs MUD/MUD vs Haplo) in an effort to keep them balanced. The conditioning regimen for both arms will be mainly Busulfan/Fludarabine (A Total Body Irradiation based conditioning regimen will be allowed for diseases such as ALL) The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus for patients with a 10/10 matched related or unrelated donor and of high dose cyclophosphamide on Days +3 and +4 followed by tacrolimus and mycophenolate for patients with a haploidentical donor.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 43
Est. completion date December 2027
Est. primary completion date June 8, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - High risk hematologic malignancy justifying the need for an allogeneic hematopoetic stem cell transplantation: AML, ALL, CML in accelerated or blast phase, MDS/MPN, NHL, Hodgkin lymphoma, and multiple myeloma - Creatinine clearance > 40 - Adequate hepatic function - Normal cardiac function (EF > 50%) Exclusion Criteria: - Patients with hematologic malignancies for which transplant is not the only curative option, such as AML with good or intermediate cytogenetics or molecular markers in CR1 or CML in chronic phase - Inability to identify an 10/10 HLA-Matched Donor (related or unrelated) or a haploidentical donor - Active malignant disease relapse - Active, uncontrolled infection, uncontrolled cardiac angina, symptomatic congestive heart failure - Life expectancy <3 months - Pregnancy or lactation - Patients may not be receiving any other investigational agents in the last 28 days - Patients with chronic myeloid leukemia in first chronic phase

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide
Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).
abatacept
Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
Methotrexate
standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11
Tacrolimus
Tacrolimus per institutional guidelines

Locations

Country Name City State
United States UC San Diego Moores Cancer Center La Jolla California

Sponsors (2)

Lead Sponsor Collaborator
Dimitrios Tzachanis, MD PhD Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary occurrence of moderate and severe chronic GVHD at one year post transplant The occurrence of moderate and severe chronic GVHD at one year post Chronic GVHD will be diagnosed and staged according to the previously published and widely accepted National Institutes of Health consensus criteria through study completion, an average of 1 year
Secondary GVHD- and relapse- free survival by one year post transplant GVHD- and relapse- free survival will be defined as the absence of acute GVHD Grade III or IV or moderate or severe chronic GVHD or relapse or non-relapse mortality by one year post transplant. Acute GVHD will be diagnosed and graded according to Glucksberg criteria through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT03483194 - Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) Phase 2/Phase 3
Recruiting NCT03735992 - Mind-body Medicine for Patients With Malignant Hematological Diseases N/A
Recruiting NCT04959175 - Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Phase 1/Phase 2
Withdrawn NCT04275154 - Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
Terminated NCT00957580 - Trial of Pimasertib in Hematological Malignancies Phase 2
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00389428 - Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. Phase 1
Completed NCT02193880 - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) N/A
Recruiting NCT00071045 - Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Not yet recruiting NCT05054231 - Immunological Profile for Patients Treated With CAR-T Cells N/A
Completed NCT02650791 - Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study Phase 3
Completed NCT01362179 - National Marrow Donor Program Long-Term Donor Follow-Up
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Terminated NCT03648372 - A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System Phase 1/Phase 2
Recruiting NCT03320915 - Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT Phase 2
Recruiting NCT06422533 - Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients N/A
Terminated NCT02895529 - A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Phase 4
Recruiting NCT03083327 - Prophylactic Early PN in HPT/BMT N/A
Recruiting NCT03743480 - Early Palliative Care and Hematological Cancer Patients N/A
Completed NCT02635984 - Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens Phase 3